Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: February 1, 2023

Details for Patent: 7,230,098

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,230,098 protect, and when does it expire?

Patent 7,230,098 protects XALKORI and is included in one NDA.

This patent has forty-six patent family members in thirty-two countries.

Summary for Patent: 7,230,098
Title:Aminoheteroaryl compounds as protein kinase inhibitors
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET ##STR00001##
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Bhumralkar; Dilip (San Diego, CA), Botrous; Iriny (San Diego, CA), Chu; Ji Yu (Fremont, CA), Funk; Lee A. (Oceanside, CA), Hanau; Cathleen Elizabeth (Chesterfield, MO), Harris; G. Davis (Chesterfield, MO), Jia; Lei (San Diego, CA), Johnson; Joanne (Guilderland, NY), Kolodziej; Stephen A. (Ballwin, MO), Kung; Pei-Pei (San Diego, CA), Li; Xiaoyuan (Sharon) (Los Altas, CA), Lin; Jason (Qishen) (San Diego, CA), Meng; Jerry Jialun (San Diego, CA), Nambu; Mitchell David (San Diego, CA), Nelson; Christopher G. (Fresno, CA), Pairish; Mason Alan (San Diego, CA), Shen; Hong (San Diego, CA), Tran-Dube; Michelle (La Jolla, CA), Walter; Allison (Rexford, NY), Zhang; Fang-Jie (Sunnyvale, CA), Zhang; Jennifer (Foster City, CA)
Assignee: Sugen, Inc. (South San Francisco, CA)
Application Number:10/786,610
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,230,098

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,230,098

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2114 See Plans and Pricing
Australia 2004215428 See Plans and Pricing
Brazil PI0407827 See Plans and Pricing
Canada 2517256 See Plans and Pricing
China 103265477 See Plans and Pricing
China 1777427 See Plans and Pricing
Costa Rica 7961 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.